Search
Search
#1. Definition of relapse-free survival - NCI Dictionary of Cancer ...
relapse -free survival ... In cancer, the length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that ...
#2. Are there differences between progression-free survival ...
Note that under STEEP DFS (disease-free survival) is interchangeable with recurrence-free survival. Relapse–free survival is defined as any disease recurrence ( ...
#3. What do clinical trial results mean? | Cancer Research UK
Disease free survival (DFS), The time between treatment aimed at curing cancer, and signs that it has come back ; Progression free survival (PFS) ...
#4. Progression-free survival - Wikipedia
In oncology, PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically. Similarly, ...
#5. Disease-Free Survival As a Clinical Trial Endpoint
Unlike progression-free survival in the advanced cancer setting, which refers to time from treatment to disease progression (or death) in ...
#6. Disease-free survival versus overall survival as a primary end ...
由 DJ Sargent 著作 · 2005 · 被引用 704 次 — Eighty percent of recurrences were in the first 3 years; 91% of patients with recurrence by 3 years died before 5 years. Correlation between 3-year DFS and 5- ...
#7. Recurrence Free Survival - an overview | ScienceDirect Topics
Treatment and Prognosis ... Prolonged recurrence-free and overall survival is typical for CPP, with 5-year survival rates reaching upward of 80% following ...
#8. Patient Centered Approach: What Do Efficacy Endpoints Mean?
Disease Free Survival (DFS). – Time to Treatment Discontinuation ... Quality of life versus length of life versus cost – means different.
#9. Survival endpoints in colorectal cancer and the effect of ...
However, the difference was larger for stage II (68 vs 60%) than for stage ... The use of disease-free survival (DFS) rather than overall ...
#10. Association of progression-free or event-free survival with ...
Disease -free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 ...
#11. Comparison of Duration of Response vs Conventional ...
... changes in tumor response may inform disease prognosis and patient survival, objective response rate (ORR) and progression-free survival ...
#12. Predicting Progression-Free Survival Using MRI-Based ...
PFS was defined from the 1st day of treatment to the date of disease progression (local recurrence or distant metastasis), death for any cause, ...
#13. Relapse-Free Survival as a Surrogate for Overall Survival in ...
由 S Suciu 著作 · 2018 · 被引用 60 次 — With a median follow-up of seven years, 12 of 13 trials showed a consistency between the IFN vs No IFN differences regarding RFS (hazard ratio [ ...
#14. Definition of disease-free survival: this is my truth–show me ...
The authors recommend that the definition of DFS should include as events recurrence or relapse of colorectal cancer, all second cancers, or death from any ...
#15. Are progression-free and disease-free survival the new gold ...
The clinical relevance of PFS is unclear. As an independent outcome, PFS/DFS is most clinically relevant when there is the smallest benefit in ...
#16. Comparisons of recurrence-free survival and overall ... - PLOS
A meta-analysis which involved 2062 patients showed that MW ablation and RF ablation had similar 1–5-year overall survival, disease-free ...
#17. Disease-free survival (DFS) | Cancer.Net
Disease -free survival (DFS) ... The measure of time after treatment during which no sign of cancer is found. This term can be used for an individual or for a ...
#18. Evaluation of Overall Response Rate and Progression-Free ...
We evaluated RECIST criteria–based overall response rate (ORR) and progression-free survival (PFS) as potential surrogate endpoints of ...
#19. Recurrence-Free Survival Benefit Maintained With Adjuvant ...
In recurrence-free survival subgroup analyses, hazard ratios by disease stage were 0.70 (95% CI = 0.50–0.98) among 165 vs 147 patients with ...
#20. 當代醫藥法規月刊第102期
102 18 A. 整體存活(Overall survival ， OS) ： 定義為在ITT ... 此類指標包括下列各項： (1) 無疾病存活期(Disease-free survival，DFS)：定義為從隨機分配至疾病 ...
#21. Prediction of survival benefits from progression ... - BMJ Open
To investigate whether progression-free survival (PFS) can be considered a surrogate endpoint for overall survival (OS) in advanced non-small-cell lung cancer ( ...
#22. 6 versus 12 months of adjuvant trastuzumab for HER2-positive ...
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a ...
#23. Disease-Free Survival vs. Progression-Free ... - CheckRare
Dr Paolo Ghia discusses the difference between disease-free survival (DFS) and progression-free survival (PFS) within the context of the ...
#24. Appendix 1 to the guideline on the evaluation of anticancer ...
The use of progression-free survival (PFS) or disease-free survival (DFS) as endpoint in clinical efficacy trials presents several ...
#25. Primary end points of clinical trials - overall survival versus ...
This roundtable discussion looks at the advantages and disadvantages of overall survival and progression free survival as primary end points of clinical ...
#26. Merck's KEYTRUDA® (pembrolizumab) Showed Statistically
... Significant Improvement in Disease-Free Survival Versus Placebo as ... adjuvant KEYTRUDA reduced the risk of disease recurrence or death ...
#27. Sa1234 OVERALL SURVIVAL, DISEASE-FREE SURVIVAL ...
Graph 2Forest plot of disease-free Survival for Endoscopic Submucosal Dissection (ESD) versus Gastrectomy for Early Gastric Cancer.
#28. 癌症臨床試驗的常用終點 - 呼吸希望
疾病無惡化存活期(Progression-free survival, PFS)：這是指從治療開始直至檢測到疾病惡化之間的時間。這通常用於研究不可能完全消除的晚期疾病 32 。疾病無惡化存活期定義為 ...
#29. Progression-free survival as a surrogate endpoint for overall ...
Although there may be clinical remission or disease stabilization in many AGC patients who receive first-line chemotherapy, most will ultimately ...
#30. On the relation between improved loco-regional control and ...
Loco-regional control (LRC) and disease-free-survival (DFS) are important clinical endpoints in head-and-neck cancer (HNC). However, an improvement in LRC ...
#31. Predictive Ability for Disease-Free Survival of the GRade, Age ...
right tumors), and histology (clear cell carcinoma vs. papillary/chromo-phobe cells vs. others). The median period of follow-up was evaluated ...
#32. Clinical Significance of the Relationship between Progression ...
Type of relapse (refractory/sensitive) and the number of regimens ... Progression-free survival (PFS) and OS are two common endpoints in cancer trials.
#33. Disease-Free Survival vs. Progression-Free ... - YouTube
The CAPTIVATE study evaluated ibrutinib plus venetoclax as a first-line treatment for chronic lymphocytic leukemia (CLL); data from this trial ...
#34. What Survival Rate Really Means With Cancer - Verywell Health
Disease -free survival is a measure of the number of people who are expected to be free from cancer for a particular amount of time.3 This is ...
#35. AI3 Disease-Free Survival (DFS) As a Surrogate Endpoint for ...
A systematic literature review was conducted to identify EC/GEJ trials that reported OS and DFS, or progression-free survival (PFS) ...
#36. Disease-free and overall survival after neoadjuvant ...
Mastectomy versus BCS was not a significant predictor for disease-free survival when adjusted for the former variables (unadjusted HR 2.13 ...
#37. Disease-free survival in patients with non-metastatic breast ...
Disease -free survival (DFS) is defined as the time between the beginning of the treatment and disease progression or death from any cause. ... Machado KK, Katz A, ...
#38. Adjuvant Pembrolizumab versus Placebo in Resected Stage ...
Abstract Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival ...
#39. a review of studies examining the relationship between - NICE ...
progression -free rather than disease-free survival. The main focus was therefore advanced or metastatic cancer. Results. Nineteen papers were included in ...
#40. Response to treatment | HemOnc.org - A Hematology ...
2.3 Disease-free interval (DFI); 2.4 Disease-free survival (DFS) ... De Gramont A. Disease-free survival versus overall survival as a ...
#41. Ten years' disease-free survival of advanced epithelial ovar...
Ten years' disease-free survival of advanced epithelial ovarian cancer treated by cytoreductive surgery plus hyperthermic intraperitoneal ...
#42. Understanding the endpoints in oncology: overall survival ...
Overall Survival versus Survival Rate: The term overall survival can be easily ... Disease free survival: time to disease reoccurring.
#43. 癌症病人預後的評估工具簡介：存活期、反應率
無病存活率（disease-free survival, DFS）是指病人診斷癌症接受完整治癒性療法後開始觀察，經過一段時間後，其復發或死亡的病人比率（換個概念就是活著且無復發轉移的病人 ...
#44. The Value of Progression-Free Survival in Metastatic Breast ...
Progression -free survival (PFS), defined in clinical trials as the ... and duration of stable disease versus progressive disease and death, ...
#45. Recurrence and Disease-Free Survival in Head and Neck ...
Recurrence was observed in 66% of cases with median disease-free survival of 12 months and perineural invasion was noted in 12% cases. We found ...
#46. A novel machine learning algorithm to predict disease free ...
A novel machine learning algorithm to predict disease free survival after ... MO Guba; (V) Data analysis and interpretation: MB Schoenberg, AV Bazhin, ...
#47. Adjuvant Nivolumab Demonstrates Improved Disease-Free ...
Patients with muscle invasive urothelial carcinoma who received adjuvant nivolumab experienced a longer disease-free survival compared with ...
#48. Estimating Relapse Free Survival as a Net Probability
The occurrence of death not related to the disease or secondary tumours different from breast cancer (defined as absorbing events) may be observed for some ...
#49. Progression Free Survival (PFS), and ... - ASH Publications
Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice ( ...
#50. DFS ; Disease-Free Survival - 生技投資第一站 - Genet觀點
無疾病存活期(簡稱DFS；Disease-Free Survial )，又稱無復發存活期(簡稱RFS；Relapse-Free Survival) : 臨床實驗結果的指標，也就是說病患已經沒有 ...
#51. Overall survival vs disease-free survival and other surrogate ...
Disease -free survival (DFS) is a surrogate endpoint often used in oncology RCTs. It captures two events: disease recurrence or death ...
#52. Preoperative CT-based Deep Learning Model for Predicting ...
A deep learning model for preoperative chest CT predicted disease-free survival in patients with lung adenocarcinoma.
#53. Pembrolizumab Shows Improvements in Disease-Free ...
Pembrolizumab Shows Improvements in Disease-Free Survival as Adjuvant Treatment for Non-Small Cell Lung Cancer. January 18, 2022.
#54. Disease-Free Survival Predicts Overall Survival in Localized ...
2021年11月7日 — For patients with vs without recurrence, the median OS after each landmark following initial nephrectomy was 2.4 vs 9.7 years at 1 year ( ...
#55. OS vs. PFS: What You Need to Know - Metastatic Trial Talk
Clinical trials are set up to look at specific outcomes. In some trials, researchers set out to look at progression-free survival (PFS), ...
#56. disease free survival | Primary Research | Search results page 1 ...
RCT (n=1206) reports at 4yrs, patients treated with NAB-paclitaxel had significantly better invasive disease–free survival v soluble ...
#57. KEYNOTE-564 Demonstrates Improvement in Disease-Free ...
... KEYNOTE-564 Study kidney cancer, improved disease free survival ... and clinically meaningful improvement in DFS vs placebo, Rana McKay, ...
#58. Adjuvant Atezolizumab Did Not Show Disease-Free Survival Benefit ...
Adjuvant therapy with atezolizumab (Tecentriq) did not meet the primary end point of disease-free survival (DFS) in patients with muscle-invasive urothelial ...
#59. Disease-Free Survival | Profiles RNS
"Disease-Free Survival" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings).
#60. 整體存活率vs 無病存活率 - wenwu
中位存活率（median overall survival）為14個月，表示約有一半的病人存活超過14個月。 無病存活率( disease-free survival ). 那無病存活率又是甚麼呢? 在整體存活率中， ...
#61. Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs ...
Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial ...
#62. Tipifarnib as maintenance therapy did not improve disease-free ...
The primary objective was to compare the disease-free survival (DFS) between the two ... Median DFS was 8.9 vs 5.3 months, for tipifarnib vs observation ...
#63. Puma Biotechnology Presents 3-Year ... - Puma Biotechnology, Inc.
Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase ... of invasive disease recurrence or death versus placebo (hazard ratio = 0.67, ...
#64. Sutima Luangdilok, et al. Supplementary Figure 2. Disease-free ...
Disease -free survival (DFS) and overall survival (OS) according to estrogen receptor (ER) status and strength of ER ... ER status (ER-positive vs.
#65. 【relapse free survival定義】Definitionofrelapse-freesu... +1
無進展生存期（progression-free survival，PFS）., 目前對DFS存在不同定義和解釋，不同研究者之間在判斷疾病復發或進展... 3) 無 ...
#66. Merck's KEYTRUDA® (pembrolizumab ... - Yahoo Finance
... Significantly Improved Overall Survival (OS) Versus Placebo in ... an improvement in overall survival (OS), progression-free survival ...
#67. Superior Graft-versus-Host Disease-Free Relapse-Free Survival in ...
Superior Graft-versus-Host Disease-Free Relapse-Free Survival in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation with Anti-Thymocyte Globulin ( ...
#68. Merck's KEYTRUDA® (pembrolizumab ... - Business Wire
KEYTRUDA Significantly Improved Overall Survival (OS) in Patients ... an improvement in overall survival (OS), progression-free survival ...
#69. Dr. Morris on rPFS as an Endpoint in Clinical Trials - OncLive
... discusses the use of radiographic progression-free survival as an endpoint in prostate cancer clinical trials.
#70. Nivolumab Achieves Durable Responses and Extends OS ...
Nivolumab Achieves Durable Responses and Extends OS Versus Sorafenib ... include objective response rate, progression-free survival (PFS), ...
#71. ImmunityBio Announces Results of Phase 2 Metastatic ...
The median overall survival in this highly advanced group of ... The primary objective of Cohorts A and B is progression-free survival (PFS) ...
#72. More Support for Laparoscopic Hysterectomy for Early ...
Similar long-term survival, oncologic outcomes in randomized trial ... disease-free survival (DFS; 90.3% vs 84.1%), overall survival (OS; ...
#73. Sugemalimab Demonstrates Statistically Significant Overall
... survival with sugemalimab plus chemotherapy versus placebo plus... ... which met the primary endpoint of progression-free survival (PFS) ...
#74. Long term disease-free survival in acute leukemia patients ...
Patient-donor human leukocyte antigen (HLA) disparity of three antigens was 37% in the graft-versus-host disease (GvHD) and 29% in the rejection directions. All ...
#75. Sugemalimab Demonstrates Statistically Significant Overall ...
... of overall survival with sugemalimab plus chemotherapy versus ... of progression-free survival (PFS) and were recently published in .1.
#76. Enhertu granted Priority Review in the US for patients with ...
... reduced the risk of disease progression or death by 72% versus ... the unprecedented progression-free survival benefit in this setting.
#77. New Combo Therapy for Breast Implant–Associated Lymphoma
Patients with infiltrative disease had a significantly worse 2-year progression-free survival than those with in situ/mixed disease, ...
#78. Imfinzi plus chemotherapy reduced risk of death by 20% in 1st ...
... significant and clinically meaningful improvement in overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone ...
#79. Phase 3 Data for Pembrolizumab in Hepatocellular ...
... with advanced hepatocellular carcinoma (HCC) significant improvements in overall survival (OS), progression-free survival (PFS), ...
#80. Sugemalimab plus chemo boosts lung cancer survival, trial ...
Sugemalimab plus chemo boosts lung cancer survival, trial reveals ... in both progression-free survival (PFS) and overall survival (OS), ...
#81. Elacestrant Impresses in EMERALD Trial of Breast Cancer
... improvement in progression-free survival versus standard-of-care ... experience disease progression often involving mutations in ESR1.
#82. Merck's KEYTRUDA® Significantly Improved Overall Survival ...
KEYNOTE-394 is the first trial with an anti-PD-1/L1 as a second-line monotherapy treatment to show an improvement in overall survival (OS), progression-free ...
#83. Analysis shows strength of abiraterone/ADT efficacy in non ...
... metastasis-free survival boost versus treatment with ADT alone in ... Additionally, patients were required to have high-risk disease or ...
#84. Pancreatic Cancer Prognosis, Malnutrition Risk, and Quality of ...
... changes in QOL indicators and the Progression-Free Survival and Overall Survival in ... to symptoms of the disease that could compromise nutritional status.
#85. OS、PFS、DFS 有什麼區別？一文搞懂6 大腫瘤臨床試驗終點
腫瘤大小分為兩組(<3cm or <3cm)等等， : 來看Disease-specific survial(DSS)或Recurrent-free survival(RFS)， ... , 總生存（Overall survival，OS）. 定義為：從...
#86. Diminished Disease-Free Survival After Lobectomy: Screening ...
(1) Five-year disease-free fatality (16.1%) was 58% as high as 5-year lung cancer fatality (27.6%); (2) disease-free survival was reduced by 6.9-years (95% ...
#87. Cardiff Oncology Announces New Data from Lead Clinical ...
"The objective response rate and median progression free survival ... 33 of 35 (94%) had a best response of disease control (CR + PR + SD) ...
#88. Multiple Myeloma Response-CR or VGPR- NO Difference
Multiple Myeloma an incurable disease, but I have spent the last 25 years in ... CR or VGPR with either overall survival or progression-free survival both ...
#89. 생존 분석 (Survival analysis)
생존 분석 (Survival analysis) Start. BioinformaticsAndMe. #생존분석에 대한 R 분석 예제는 아래 포스팅 참조.
#90. 'Ibrance's exposure irrelevant to failure in early breast cancer ...
In addition, the independent data monitoring committee (DMC) concluded that Ibrance failed to improve invasive disease-free survival (iDFS) ...
#91. Drugs—Advances in Research and Application: 2013 Edition
5-year progression-free survival rate between the maintenance and induction groups in patients with high progression risk (100.0 vs. 69.3; P 0.047).
#92. Management of Esophageal Cancer, An Issue of Surgical ...
Evaluation focused on patterns of recurrence, and in particular outcomes in those ... Consolidation did not prolong progression-free survival; however, ...
#93. Gynaecologic Cancer: A Handbook for Students and Practitioners
Chemoradiation also improved disease-free survival from 37% to 54% and 5-year ... chemoradiation was signiicantly greater than radiotherapy alone (67% vs.
#94. Cancer: Principles and Practice of Oncology-Advances in Oncology
Evaluation of tumor response, disease control, progression-free survival, ... Disease-free survival versus overall survival as a primary end point for ...
recurrence free survival vs progression free survival 在 Disease-Free Survival vs. Progression-Free ... - YouTube 的必吃
The CAPTIVATE study evaluated ibrutinib plus venetoclax as a first-line treatment for chronic lymphocytic leukemia (CLL); data from this trial ... ... <看更多>